Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Off-label indications for imiquimod Ganjian S; Ourian AJ; Shamtoub G; Wu JJ; Murase JEDermatol Online J 2009[May]; 15 (5): 4Due to the ability of imiquimod (Aldara, 3M Pharmaceuticals) to rapidly and potently stimulate both innate and adaptive arms of the immune system, imiquimod has rapidly been recognized as a potential candidate for off-label use in over 60 conditions as presented in numerous case reports, letters, and small trials. It is our goal to examine and consolidate this impressive body of literature in order to provide the practicing dermatologist with a quick reference of the conditions that have been successfully treated with imiquimod, the dosages used, and the success rates of treatments.|Adjuvants, Immunologic/administration & dosage/adverse effects/*therapeutic use[MESH]|Aminoquinolines/administration & dosage/adverse effects/*therapeutic use[MESH]|Antineoplastic Agents/administration & dosage/adverse effects/therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use[MESH]|Humans[MESH]|Imiquimod[MESH]|Interferon Inducers/administration & dosage/adverse effects/therapeutic use[MESH]|Multicenter Studies as Topic[MESH]|Retrospective Studies[MESH]|Skin Diseases/*drug therapy[MESH] |